Pathway-based identification of SNPs predictive of survival

European Journal of Human Genetics

Volumn 19, Issue 6, 2011, Pages 704-709

  Pang, Herbert ^a   Hauser, Michael ^a   Minvielle, Stéphane ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

gene and pathway based analysis; genome wide scan; multiple myeloma; random forests; single nucleotide polymorphisms; survival

Indexed keywords

ARTICLE; CANCER SURVIVAL; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION; GENETIC IDENTIFICATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; CASE-CONTROL STUDIES; COMPUTER SIMULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, GENETIC; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS;

EID: 79956304186     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.3     Document Type: Article

References (48)

1. Chasman DI: On the utility of gene set methods in genomewide association studies of quantitative traits. Genet Epidemiol 2008; 32: 658-668.
2. Peng G, Luo L, Siu H et al: Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet 2010; 18: 111-117.
3. Ritchie MD: Using prior knowledge and genome-wide association to identify pathways involved in multiple sclerosis. Genome Med 2009; 1: 65.
4. Baranzini SE, Galwey NW, Wang J et al: Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009; 18: 2078-2090.
5. Ballard DH, Aporntewan C, Lee JY, Lee JS, Wu Z, Zhao H: A pathway analysis applied to genetic analysis workshop 16 genome-wide rheumatoid arthritis data. BMC Proc 2009; 3(Suppl 7): S91.
6. Wang K, Zhang H, Kugathasan S et al: Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 2009; 84: 399-405.
7. Wang K, Li M, Bucan M: Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet 2007; 81: 1278-1283. (Pubitemid 350211456)
8. Dinu V, Miller PL, Zhao H: Evidence for association between multiple complement pathway genes and AMD. Genet Epidemiol 2007; 31: 224-237. (Pubitemid 46493566)
9. Bureau A, Dupuis J, Falls K et al: Identifying SNPs predictive of phenotype using random forests. Genet Epidemiol 2005; 28: 171-182.
10. Chang JS, Yeh RF, Wiencke JK et al: Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 2008; 17: 1368-1373.
11. Dinu V, Zhao H, Miller P et al: Integrating domain knowledge with statistical and data mining methods for high-density genomic SNP disease association analysis. J Biomed Inform 2007; 40: 750-760. (Pubitemid 350088621)
12. Schumacher M, Binder H, Gerds T: Assessment of survival prediction models based on microarray data. Bioinformatics 2007; 23: 1768-1774. (Pubitemid 47250309)
13. Van Wieringen W, Kun D, Hampel R, Boulesteix A-L: Survival prediction using gene expression data. a review and comparison. Comput Stat Data Anal 2009; 53: 1590-1603.
14. Pang H, Datta D, Zhao H: Pathway analysis using random forests with bivariate node-split for survival outcomes. Bioinformatics 2010; 26: 250-258.
15. Ishwaran H, Kogalur U, Blackstone E, Lauer M: Random survival forests. Ann Appl Stat 2008; 2: 841-860.
16. Hothorn T, Lausen B: On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003; 43: 121-137. (Pubitemid 36715216)
17. Segal M: Regression trees for censored data. Biometrics 1988; 44: 35-47. (Pubitemid 18098810)
18. Kanehisa M, Goto S, Hattori M et al: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34: D354-D357.
19. Bender R, Augustin T, Blettner M: Generating survival times to simulate Cox proportional hazards models. Stat Med 2005; 24: 1713-1723. (Pubitemid 40754090)
20. International HapMap Consortium: A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
21. Browning BL, Browning SR: A unified approach to genotype imputation and haplotype phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009; 84: 210-223.
22. Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A: A comprehensive evaluation of SNP genotype imputation. Hum Genet 2009; 125: 163-171.
23. Avet-Loiseau H, Li C, Magrangeas F et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585-4590.
24. Storey JD, Tibshirani R: Statistical significance for genome-wide studies. PNAS 2003; 100: 9440-9445.
25. Duan S, Bleibel WK, Huang RS et al: Mapping genes that contribute to daunorubicininduced cytotoxicity. Cancer Res 2007; 67: 5425-5433. (Pubitemid 46997283)
26. Schadt EE, Molony C, Chudin E et al: Mapping the genetic architecture of gene expression in human liver. Plos Biol 2008; 6: e107.
27. Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440-2452. (Pubitemid 36542483)
28. Georgakis GV, Younes A: Cytokines and lymphomas. Cancer Treat Res 2005; 126: 69-102.
29. Hosgood III HD, Baris D, Zhang Y et al: Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008; 26: 148-151.
30. Ishitsuka K, Hideshima T, Hamasaki M et al: Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005; 106: 1794-1800. (Pubitemid 41208596)
31. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST: Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 2002; 1: 1221-1227.
32. Fuller SJ, Papaemmanuil E, McKinnon L et al: Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. Br J Haematol 2008; 142: 238-245. (Pubitemid 351987326)
33. Van de Donk NW, Bloem AC, Van der Spek E, Lokhorst HM: New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des 2006; 12: 327-340.
34. Lombardi L, Poretti G, Mattioli M et al: Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226-238. (Pubitemid 46155318)
35. Carrasco DR, Tonon G, Huang Y et al: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-325.
36. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS: Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044-3052. (Pubitemid 29200797)
37. Shi J, Tricot G, Szmania S et al: Infusion of haplo-identical killer immunoglobulinlike receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641-653.
38. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R: Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000; 95: 610-618. (Pubitemid 30041677)
39. Pappa C, Miyakis S, Tsirakis G et al: Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007; 37: 171-175. (Pubitemid 46694336)
40. Alexandrakis MG, Passam FH, Sfiridaki K et al: Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004; 28: 259-266. (Pubitemid 37550060)
41. Yamashita K, Iwasaki T, Tsujimura T et al: Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep 2002; 9: 1237-1244.
42. Kitano M, Ogata A, Sekiguchi M, Hamano T, Sano H: Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. J Bone Miner Metab 2005; 23: 48-52.
43. Brown EE, Lan Q, Zheng T et al: Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007; 120: 2715-2722. (Pubitemid 46651296)
44. Goldstein B, Hubbard A, Cutler A, Barcellos L: An application of Random Forests to a genome-wide association dataset: methodological considerations & new findings. BMC Genet 2010; 11: 49.
45. Genuer R, Poggi J, Tuleau C: Random forests: some methodological insights. Tech rep, INRIA 2008, http://hal.inria.fr/inria-00340725/en/, arXiv:0811.3619.
46. Devlin B, Risch N: A comparison of linkage disequilibrium measures for fine-mapping. Genomics 1995; 29: 311-322.
47. Meng Y, Yu Y, Cupples L, Farrer L, Lunetta K: Performance of random forest when SNPs are in linkage disequilibrium. BMC Bioinformatics 2009; 10: 78.
48. Elbers C, Van Eijk K, Franke L et al: Using genome-wide pathway analysis to unravel the etiology of complex diseases. Genet Epidemiol 2009; 33: 419-431.